<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03578796</url>
  </required_header>
  <id_info>
    <org_study_id>2016/2187-1</org_study_id>
    <nct_id>NCT03578796</nct_id>
  </id_info>
  <brief_title>Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen in Norway: A Prospective Cohort Study</brief_title>
  <official_title>Cognitive Impairment in ALS: Screening Tools, Experiences and Prognosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Western Norway University of Applied Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluate use of a translated Norwegian version of the Edinburgh cognitive and
      behavioral amyotrophic lateral sclerosis screen (ECAS-N) as an early predictor in
      car-driving, working and use of advanced life-prolonging therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cognitive impairment is present in about 30-50% of the patients with amyotrophic lateral
      sclerosis (ALS). Screening of cognitive and behavioral impairment is a distinct
      recommendation in ALS-specific health care. However, knowledge in how cognitive impairment
      shall influence health-care professionals' information given to patients and in decision
      making is lacking.

      One of the major challenges in ALS management is the decision-making on advanced therapy.
      There is a lack of knowledge in how cognitive impairment in ALS shall be interfere on complex
      medical treatment that will affect quality of life or life itself. This means significant
      implications not only to the ALS patient and the community, but also the family and
      especially the spouse. Thus, further investigation of the ECAS-N and its potential in
      clinical use is needed. The scale may contribute a more proactive treatment better tailored
      to individual needs. The objective is to evaluate if the ECAS-N can be applied as an early
      predictor in car-driving, working and use of advanced life-prolonging therapy
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Dementia Rating (CDR)</measure>
    <time_frame>8 months</time_frame>
    <description>We will use the total CDR score (minimum score = 0, maximum score = 18). Low scores indicate less problems than high scores.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Dementia Rating (CDR)</measure>
    <time_frame>4 months</time_frame>
    <description>We will use the total CDR score (minimum score = 0, maximum score = 18). Low scores indicate less problems than high scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Dementia Rating (CDR)</measure>
    <time_frame>3 years or until death</time_frame>
    <description>We will use the total CDR score (minimum score = 0, maximum score = 18). Low scores indicate less problems than high scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability in car-driving</measure>
    <time_frame>8 months</time_frame>
    <description>We will use a categorical variable (yes or no) and time of change to reduced function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability in car-driving</measure>
    <time_frame>4 months</time_frame>
    <description>We will use a categorical variable (yes or no) and time of change to reduced function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability in car-driving</measure>
    <time_frame>3 years or until death</time_frame>
    <description>We will use a categorical variable (yes or no) and time of change to reduced function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Working ability</measure>
    <time_frame>8 months</time_frame>
    <description>We will use a categorical variable (yes or no) and time of change to reduced function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Working ability</measure>
    <time_frame>4 months</time_frame>
    <description>We will use a categorical variable (yes or no) and time of change to reduced function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Working ability</measure>
    <time_frame>3 years or until death</time_frame>
    <description>We will use a categorical variable (yes or no) and time of change to reduced function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Advanced life-prolonging therapy</measure>
    <time_frame>8 months</time_frame>
    <description>We will use a categorical variable (yes or no) and time of change to reduced function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Advanced life-prolonging therapy</measure>
    <time_frame>4 months</time_frame>
    <description>We will use a categorical variable (yes or no) and time of change to reduced function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Advanced life-prolonging therapy</measure>
    <time_frame>3 years or until death</time_frame>
    <description>We will use a categorical variable (yes or no) and time of change to reduced function.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Edinburgh cognitive and behavioral amyotrophic lateral sclerosis screen-Norwegian Version (ECAS-N)</measure>
    <time_frame>4 months</time_frame>
    <description>We will use the ALS-specific sub-score (minimum score = 0, maximum score = 100), the ALS non-specific sub-score (minimum score = 0, maximum score = 36), a summed total ECAS-N score (minimum score =0, maximum score =136), the sub score of behavioural changes (minimum score = 0, maximum score = 10) and the sub score of psychotic change (minimum score = 0, maximum score = 3). A dichotomized cut-off scores for normality will also be used for the ALS-specific cut-off score of 65 or over, the non ALS-specific cut-off score of 24 or over and the total ECAS-N cut-off score of 92 or over. For the ALS-specific scores, non ALS-specific scores and total ECAS-N scores, high scores indicate less problems than low scores. For the sub score of behavioural change and the sub score of psychotic change, high scores indicate more problems than low scores.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from 4 months Edinburgh cognitive and behavioral amyotrophic lateral sclerosis screen-Norwegian Version (ECAS-N) at 8 months</measure>
    <time_frame>8 months</time_frame>
    <description>We will use the changed ALS-specific sub-score (minimum score = 0, maximum score = 100), the changed ALS non-specific sub-score (minimum score = 0, maximum score = 36), a changed summed total ECAS-N score (minimum score =0, maximum score =136), the changed sub score of behavioural changes (minimum score = 0, maximum score = 10) and the changed sub score of psychotic change (minimum score = 0, maximum score = 3). A changed dichotomized cut-off scores for normality will also be used for the ALS-specific cut-off score of 65 or over, the non ALS-specific cut-off score of 24 or over and the total ECAS-N cut-off score of 92 or over. For the ALS-specific scores, non ALS-specific scores and total ECAS-N scores, high scores indicate less problems than low scores. For the sub score of behavioural change and the sub score of psychotic change, high scores indicate more problems than low scores.</description>
  </other_outcome>
  <other_outcome>
    <measure>Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>4 months</time_frame>
    <description>We will use the total MoCA score (minimum score = 0, maximum score = 30) and a dichotomized cut-off score for normality of 26 or over. High scores indicate less problems than low scores</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from 4 months Montreal Cognitive Assessment (MoCA) at 8 months</measure>
    <time_frame>8 months</time_frame>
    <description>We will use the changed total MoCA score (minimum score = 0, maximum score = 30) and the changed dichotomized cut-off score for normality of 26 or over. High scores indicate less problems than low scores</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Persons with ALS</arm_group_label>
    <description>Persons With possible ALS-specific cognitive impairment will be tested With ECAS-N, MoCA, CDR and a questionnaire at 4 months (baseline) and 8 months (1. follow-up). Further evaluation will be with the questionnaire and CDR at each follow-up until 3 years or use of permanent ventilation support or Death. Information about use of advanced life-prolonging therapy will be collected from patient journal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ECAS-N</intervention_name>
    <description>assessing ALS-specific cognitive impairment</description>
    <arm_group_label>Persons with ALS</arm_group_label>
    <other_name>Edinburgh cognitive and behavioural ALS screen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MoCA</intervention_name>
    <description>assessing cognitive impairment</description>
    <arm_group_label>Persons with ALS</arm_group_label>
    <other_name>Montreal cognitive assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CDR</intervention_name>
    <description>assessing global cognitive impairment, as well as possible diagnosis- and Level of dementia</description>
    <arm_group_label>Persons with ALS</arm_group_label>
    <other_name>Clinical dementia rating</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Questions related to work situation and car driving</description>
    <arm_group_label>Persons with ALS</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who fullfill the inclusion criteria and attending to the ALS-clinic at HUH within
        4 months after being diagnosed with ALS.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntary informed consent

          -  Native Norwegian speaker

        Exclusion Criteria:

          -  Great difficulties in writing or reading

          -  Comorbid medical history

          -  Neurological disorders others than ALS

          -  Psychiatric history of importance to cognitive function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tina Taule, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haukeland University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tina Taule, PhD</last_name>
    <phone>+47 41694143</phone>
    <email>tina.taule@helse-bergen.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Taule, PhD</last_name>
      <phone>+47 41694143</phone>
      <email>tina.taule@helse-bergen.no</email>
    </contact>
    <contact_backup>
      <last_name>Ole-Bj√∏rn Tysnes, Professor</last_name>
      <email>ole-bjorn.tysnes@helse-bergen.no</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 1, 2018</study_first_submitted>
  <study_first_submitted_qc>July 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2018</study_first_posted>
  <last_update_submitted>August 20, 2019</last_update_submitted>
  <last_update_submitted_qc>August 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>Cognitive</keyword>
  <keyword>Predictor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

